EuroIntervention | Your reference journal for coronary, valvular and structural interventions

Your reference journal for coronary, valvular and structural interventions

Early outcomes of redo-TAVI with SAPIEN 3

Original Research

Jun 8

Early outcomes of redo-TAVI with SAPIEN 3

Giuseppe Tarantini, Radoslaw Parma, et al.

This article provides an overview of the various interventional procedures available in cardiology, including coronary, valvular, heart failure, peripheral, hypertension, and stroke interventions.

State-of-the-Art

Jun 4

TAVI and coronary interventions

Heberto Aquino Bruno, Giuseppe Tarantini, et al.

This review provides a comprehensive overview of coronary interventions related to transcatheter aortic valve implantation (TAVI), covering coronary evaluation, indications and timing of percutaneous coronary intervention, and strategies for managing coronary obstruction.

free

Flashlight

Jun 3

UNICORN technique in native valves

Jean-Benoît Veillette, Jean-Michel Paradis, et al.

This case report describes the use of the UNICORN technique to prevent left coronary obstruction during TAVI in an 84-year-old female with severe native aortic stenosis.

new issue

Jun 1

A new issue of EuroIntervention

A State-of-the-Art on TAVI and coronary interventions; early haemodynamic valve deterioration after TAVI; 30-day outcomes of redo-TAVI with SAPIEN 3; Unica device for tricuspid regurgitation; the UNICORN technique in native valves; and more

Viewpoint

Jun 1

Full-on commitment to interventional cardiology

Bernard Prendergast et al.

The content describes the rapid evolution of interventional cardiology and the growth of the PCR organization as a global platform for education, scientific exchange, and innovation in the field.

free

Original Research

May 29

Clinical benefit of RDN through 3 years

David E. Kandzari, Felix Mahfoud, et al.

This study found significant blood pressure reductions through 36 months and that nearly 9 out of 10 patients experienced a clinical benefit after radiofrequency renal denervation using the Symplicity Spyral device.

open access

Original Research

May 29

Ticagrelor versus clopidogrel in ACS with DOAC

Oskar Love Emilsson, Sasha Koul et al.

In ACS patients on DOACs undergoing PCI, ticagrelor was associated with a higher bleeding risk compared to clopidogrel, with no differences in ischemic outcomes.

Ticagrelor versus clopidogrel in ACS with DOAC

open access

Editorial

May 29

A sledgehammer or a scalpel? Refining antithrombotic therapy in anticoagulated ACS patients

Diana A. Gorog, Konstantinos Toutouzas

The SWEDEHEART registry suggests that adding ticagrelor to a direct oral anticoagulant (DOAC) in patients with non-valvular atrial fibrillation and acute coronary syndrome may be akin to using a sledgehammer where a scalpel is required.

free

Editor's Choice Podcast

Listen now

EuroPCR2026

May 26

EuroPCR 2026 award ceremony results

The EuroIntervention Awards 2026 recognise the authors, reviewers, editors and contributors whose work has had an outstanding impact on the interventional cardiovascular community over the past year. Discover the full list of winners, finalists and special mentions across all categories, highlighting excellence in scientific research, innovation, education and digital engagement.

Original Research

May 28

OCT vs angio in true LMCA bifurcation lesions: an OCTOBER substudy

Emil N. Holck, Evald H. Christiansen, et al.

This study assessed the feasibility and clinical outcomes of optical coherence tomography (OCT) guidance versus angiographic guidance in percutaneous coronary intervention (PCI) for true left main coronary artery (LMCA) bifurcation lesions. OCT guidance was feasible but with limited visibility of the LMCA ostium, and did not significantly improve clinical outcomes.

OCT vs angio in true LMCA bifurcation lesions: an OCTOBER substudy

Original Research

May 28

The DOUBLE-CHOICE Trial

Hans-Josef Feistritzer, Mohamed Abdel-Wahab, et al.

In this randomized trial, TAVI with the ACURATE neo2 valve was non-inferior to the Evolut platform, with significantly lower rates of the primary composite endpoint at 30 days, driven by lower permanent pacemaker implantation.

Editorial

May 28

An unnecessary farewell? Drawing "accurate" lessons from DOUBLE-CHOICE

Stefan Blankenberg and Sebastian Ludwig

The DOUBLE-CHOICE trial demonstrated the non-inferiority of the ACURATE neo2 transcatheter heart valve compared to other contemporary valves in the treatment of severe aortic stenosis, with lower rates of the primary endpoint and paravalvular leak.

free

Original Research

May 27

Glucocorticoids: post-TAVI pacemaker prevention

Laura Fuertes-Kenneally, Juan M. Ruiz-Nodar, et al.

This pilot randomized study explored whether short-term glucocorticoid therapy could reduce the need for permanent pacemaker implantation (PPI) after TAVI, while assessing feasibility, safety, and early efficacy signals. Patients received either standard care or a steroid regimen with methylprednisolone before TAVI and prednisone for 5 days after, with outcomes including PPI rates, new left bundle branch block, mortality, and procedural complications

Glucocorticoids: post-TAVI pacemaker prevention

Editorial

May 27

Inflammation after TAVI: an emerging therapeutic target?

Thomas Pilgrim, Ottavia Cozzi

State-of-the-Art

May 26

Timing of TAVI in AS patients

Neil J. Craig, Marc R. Dweck, et al.

This review examines the current evidence for the optimal timing of transcatheter aortic valve implantation or surgical aortic valve replacement in patients with asymptomatic severe aortic stenosis or symptomatic moderate aortic stenosis.

free